← Leaderboards
Joel Palefsky
University Of California San Francisco
$28,104,336
Attributed
$28,948,609
Total exposure
33
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$39,106,269 · 34
By mechanism
U54$19,004,325 · 10
R01$11,614,442 · 4
P01$2,067,944 · 4
T32$1,280,357 · 1
M01$1,070,968 · 6
R21$1,044,656 · 3
Top collaborators
- Ana Patricia Ortiz19 shared
- Jorge SalmerãN19 shared
- Johannes G Schweizer2 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Mayumi Nakagawa$10,306,321
- Lawrence D Kaplan$3,830,195
- Peter V Chin-Hong$2,828,474
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHiv InfectionsHuman PapillomavirusAnusWomanLesionSquamous Intraepithelial LesionHiv SeropositivityCervicalProgramsHpv-High RiskClinical TrialsHuman Papilloma Virus-Related Malignant NeoplasmResearch PersonnelCaliforniaPuerto RicoCancer RiskImmune ResponseMexicoInterestResearch StudyAlgorithmsScreeningLatin America
Grant awards (117)
CAMPO consortium: HPV-related anogenital disease in people with HIV$369,648
U54 · FY2025 · CA · contact PI
CAMPO Administrative and Coordinating Core$253,564
U54 · FY2025 · CA · contact PI
California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations$113,778
U54 · FY2025 · CA · contact PI
CAMPO Administrative and Coordinating Core$15,494
U54 · FY2025 · CA · contact PI
California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations$15,494
U54 · FY2025 · CA · contact PI
CAMPO Administrative and Coordinating Core$5,832
U54 · FY2025 · CA · contact PI
California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations$1,472,147
U54 · FY2024 · CA · contact PI
CAMPO Clinical Trials Program$719,930
U54 · FY2024 · CA · contact PI
CAMPO Administrative and Coordinating Core$325,348
U54 · FY2024 · CA · contact PI
California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations$1,803,929
U54 · FY2023 · CA · contact PI
CAMPO Clinical Trials Program$867,605
U54 · FY2023 · CA · contact PI
CAMPO Administrative and Coordinating Core$410,159
U54 · FY2023 · CA · contact PI
California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations$32,114
U54 · FY2023 · CA · contact PI
CAMPO Clinical Trials Program$834,971
U54 · FY2022 · CA · contact PI
Mechanisms of disparities in the natural history of oral and oropharyngeal HPV infection among persons living with HIV: the CAMPO oral cohort study$747,144
R56 · FY2022 · DE
CAMPO Administrative and Coordinating Core$474,569
U54 · FY2022 · CA · contact PI
CAMPO Administrative and Coordinating Core$252,748
U54 · FY2022 · CA · contact PI
California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations$252,748
U54 · FY2022 · CA · contact PI
California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations$153,401
U54 · FY2022 · CA · contact PI
Implementation and evaluation of multiple recruitment research strategies for persons living with HIV in the CAMPO clinical trials in the Puerto Rico site$134,194
U54 · FY2022 · CA · contact PI
CAMPO Administrative and Coordinating Core$134,194
U54 · FY2022 · CA · contact PI
California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations$55,396
U54 · FY2022 · CA · contact PI
CAMPO Administrative and Coordinating Core$55,396
U54 · FY2022 · CA · contact PI
Characterization of the cervical fungal communities modulating high-risk HPV infections in Hispanic Women Living with HIV (WLWH)$23,282
U54 · FY2022 · CA · contact PI
California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations$1,751,091
U54 · FY2021 · CA · contact PI
CAMPO Clinical Trials Program$850,637
U54 · FY2021 · CA · contact PI
CAMPO Administrative and Coordinating Core$416,839
U54 · FY2021 · CA · contact PI
(PQ4) Anal HPV infection and anal HSIL among HIV-infected MSM aged 50+ years$278,386
R01 · FY2021 · CA · contact PI
Cervical Cancer, Aging, and Psychological Distress among HIV-positive Women in Mexico and Puerto Rico: An exploratory sub-study of the CAMPO Consortium Clinical Trials Program$252,748
U54 · FY2021 · CA · contact PI
CAMPO Administrative and Coordinating Core$252,748
U54 · FY2021 · CA · contact PI
CAMPO Administrative and Coordinating Core$175,271
U54 · FY2021 · CA · contact PI
California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations$175,271
U54 · FY2021 · CA · contact PI
California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations$1,723,723
U54 · FY2020 · CA · contact PI
CAMPO Clinical Trials Program$845,784
U54 · FY2020 · CA · contact PI
CAMPO Administrative and Coordinating Core$373,055
U54 · FY2020 · CA · contact PI
(PQ4) Anal HPV infection and anal HSIL among HIV-infected MSM aged 50+ years$257,257
R01 · FY2020 · CA · contact PI
CAMPO Global Cancer Health Disparities Supplement$194,934
U54 · FY2020 · CA · contact PI
CAMPO Administrative and Coordinating Core$194,934
U54 · FY2020 · CA · contact PI
California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations$190,646
U54 · FY2020 · CA · contact PI
CAMPO Administrative and Coordinating Core$190,646
U54 · FY2020 · CA · contact PI
California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations$1,443,116
U54 · FY2019 · CA · contact PI
CAMPO Clinical Trials Program$866,865
U54 · FY2019 · CA · contact PI
(PQ4) Anal HPV infection and anal HSIL among HIV-infected MSM aged 50+ years$563,222
R01 · FY2019 · CA · contact PI
CAMPO Administrative and Coordinating Core$330,076
U54 · FY2019 · CA · contact PI
New therapeutic HPV vaccines for HIV infected men and women$198,125
R01 · FY2019 · CA · contact PI
(PQ4) Anal HPV infection and anal HSIL among HIV-infected MSM aged 50+ years$791,933
R01 · FY2018 · CA · contact PI
New therapeutic HPV vaccines for HIV infected men and women$198,125
R01 · FY2018 · CA · contact PI
The Microbiome and Anal Cancer Pathogenesis in HIV-infected Men who have Sex with Men$79,250
R03 · FY2018 · CA · contact PI
(PQ4) Anal HPV infection and anal HSIL among HIV-infected MSM aged 50+ years$756,373
R01 · FY2017 · CA · contact PI
New therapeutic HPV vaccines for HIV infected men and women$198,125
R01 · FY2017 · CA · contact PI
(PQ5) Role of HIV-associated cellular miRNAs in HPV 16-induced pathogenesis$198,125
R21 · FY2017 · CA · contact PI
The Microbiome and Anal Cancer Pathogenesis in HIV-infected Men who have Sex with Men$79,250
R03 · FY2017 · CA · contact PI
HPV 2017-International Papillomavirus Conference & Clinical and Public Health Workshops$3,000
R13 · FY2017 · CA · contact PI
(PQ4) Anal HPV infection and anal HSIL among HIV-infected MSM aged 50+ years$787,905
R01 · FY2016 · CA · contact PI
(PQ5) Role of HIV-associated cellular miRNAs in HPV 16-induced pathogenesis$237,750
R21 · FY2016 · CA · contact PI
HPV-related neoplasia among HIV-seropositive Indian men who have sex with men$151,427
R21 · FY2012 · CA · contact PI
Incidence of HIV among Indian men who have sex with men$146,684
R21 · FY2012 · CA · contact PI
E6 Oncoprotein Based Rapid Test for Anal Neoplasia$338,612
R43 · FY2011 · CA
Incidence of HIV among Indian men who have sex with men$181,846
R21 · FY2011 · CA · contact PI
HPV-related neoplasia among HIV-seropositive Indian men who have sex with men$128,824
R21 · FY2011 · CA · contact PI
Determinants of Participation in an Anal Cancer Prevention Trial$500,000
RC1 · FY2010 · CA · contact PI
E6 Oncoprotein Based Rapid Test for Anal Neoplasia$353,742
R43 · FY2010 · CA
Determinants of Participation in an Anal Cancer Prevention Trial$499,999
RC1 · FY2009 · CA · contact PI
ORAL S100A9 (CALPROTECTIN) IN HIV INFECTION$187,878
P01 · FY2007 · DE · contact PI
UCSF Predoctoral Clinical Research Training Program (RMI)$605,641
T32 · FY2006 · RR · contact PI
Anal HPV Infection and ASIL in HIV+ and HIV- Women$204,327
R01 · FY2006 · CA · contact PI
Anal HPV Infection and ASIL in HIV+ and HIV- Women$755,373
R01 · FY2005 · CA
UCSF Predoctoral Clinical Research Training Program(RMI)$674,716
T32 · FY2005 · RR
ORAL S100A8 AND S100A9 (CALPROTECTIN) IN HIV INFECTION$198,145
P01 · FY2005 · DE
Anal HPV Infection and ASIL in HIV+ and HIV- Women$188,272
R01 · FY2005 · CA
CLINICAL AND LABORATORY CORE$185,000
P01 · FY2005 · DE
HPV AND MRPs IN ORAL CANCER PATHOGENESIS$149,682
P01 · FY2005 · DE
ANAL HPV &ASIL IN HIV+ &HIV- WOMEN$99,180
M01 · FY2005 · RR
ANAL HPV INFECTION AND ASIL IN HIV+ AND HIV- MEN$46,530
M01 · FY2005 · RR
INFRARED COAGULATOR FOR SQUAMOUS INTRAEPITHELIAL NEOPLASIA OF ANUS IN HIV+$29,387
M01 · FY2005 · RR
SGN-00101 IN HIGH-GRADE ANAL INTRAEPITHELIAL NEOPLASIA (AIN) IN HIV+ INDIVIDUALS$24,490
M01 · FY2005 · RR
PREVALANCE AND RISK FACTORS FOR ANAL HPV INFECTION AND ANAL SQUAMOUS INTRAEPI$17,143
M01 · FY2005 · RR
Anal HPV Infection and ASIL in HIV+ and HIV- Women$999,803
R01 · FY2004 · CA
NATURAL HX OF PAPILLOMA-ASSOCIATED MUCOSAL LESIONS, NORMAL AND IMMUNOSUPPRESSED$206,451
M01 · FY2004 · RR
ANAL HPV &ASIL IN HIV+ &HIV- WOMEN$191,296
M01 · FY2004 · RR
Anal HPV Infection and ASIL in HIV+ and HIV- Women$183,939
R01 · FY2004 · CA
SGN-00101 IN HIGH-GRADE ANAL INTRAEPITHELIAL NEOPLASIA (AIN) IN HIV+ INDIVIDUALS$175,199
M01 · FY2004 · RR
Anal HPV Infection and ASIL in HIV+ and HIV- Women$167,271
R01 · FY2004 · CA
EBV AND RESPONDING HOST GENES IN HIV INFECTION$149,492
P01 · FY2004 · DE
HPV AND MRPs IN ORAL CANCER PATHOGENESIS$146,536
P01 · FY2004 · DE
INFRARED COAGULATOR FOR SQUAMOUS INTRAEPITHELIAL NEOPLASIA OF ANUS IN HIV+$6,628
M01 · FY2004 · RR
Anal HPV Infection and ASIL in HIV+ and HIV- Women$811,730
R01 · FY2003 · CA
Anal HPV Infection and ASIL in HIV+ and HIV- Women$183,027
R01 · FY2003 · CA
Anal HPV Infection and ASIL in HIV+ and HIV- Women$162,828
R01 · FY2003 · CA
HPV AND MRPs IN ORAL CANCER PATHOGENESIS$137,637
P01 · FY2003 · DE
Anal HPV Infection and ASIL in HIV+ and HIV- Women$791,047
R01 · FY2002 · CA
Anal HPV Infection and ASIL in HIV+ and HIV- Women$158,515
R01 · FY2002 · CA
HPV AND MRPs IN ORAL CANCER PATHOGENESIS$137,637
P01 · FY2002 · DE
EBV AND RESPONDING HOST GENES IN HIV INFECTION$103,677
P01 · FY2002 · DE
NATURAL HISTORY OF ANAL NEOPLASIA IN HIV INFECTED MEN$75,000
R01 · FY2002 · CA
PHASE I/II STAGE OPEN LABEL NONCOMPARATIVE STUDY OF DFMO IN HIV INFECTED MEN$68,666
M01 · FY2002 · RR
NATURAL HISTORY OF ANAL NEOPLASIA--ACTG 216$68,666
M01 · FY2002 · RR
NATURAL HISTORY OF ANAL NEOPLASIA IN HIV INFECTED MEN$994,665
R01 · FY2001 · CA
Anal HPV Infection and ASIL in HIV+ and HIV- Women$831,665
R01 · FY2001 · CA
HPV AND MRPs IN ORAL CANCER PATHOGENESIS$137,637
P01 · FY2001 · DE
EBV AND RESPONDING HOST GENES IN HIV INFECTION$136,852
P01 · FY2001 · DE
Anal HPV Infection and ASIL in HIV+ and HIV- Women$107,803
R01 · FY2001 · CA
EBV AND RESPONDING HOST GENES IN HIV INFECTION$103,677
P01 · FY2001 · DE
EPITHELIAL/STROMAL INTERACTIONS IN ORAL CANCER$103,677
P50 · FY2001 · DE
EPITHELIAL/STROMAL INTERACTIONS IN ORAL CANCER$103,677
P50 · FY2001 · DE
EBV AND RESPONDING HOST GENES IN HIV INFECTION$103,677
P01 · FY2001 · DE
NATURAL HISTORY OF ANAL NEOPLASIA--ACTG 216$68,666
M01 · FY2001 · RR
PHASE I/II STAGE OPEN LABEL NONCOMPARATIVE STUDY OF DFMO IN HIV INFECTED MEN$68,666
M01 · FY2001 · RR
PHASE I/II STAGE OPEN LABEL NONCOMPARATIVE STUDY OF DFMO IN HIV INFECTED MEN$0
M01 · FY2001 · RR
NATURAL HISTORY OF ANAL NEOPLASIA--ACTG 216$0
M01 · FY2001 · RR
NATURAL HISTORY OF ANAL NEOPLASIA IN HIV INFECTED MEN$969,726
R01 · FY2000 · CA
EBV AND RESPONDING HOST GENES IN HIV INFECTION$190,417
P01 · FY2000 · DE
EPITHELIAL/STROMAL INTERACTIONS IN ORAL CANCER$109,816
P50 · FY2000 · DE
EPITHELIAL/STROMAL INTERACTIONS IN ORAL CANCER$105,410
P50 · FY2000 · DE
PHASE I/II STAGE OPEN LABEL NONCOMPARATIVE STUDY OF DFMO IN HIV INFECTED MEN$0
M01 · FY2000 · RR
EBV AND RESPONDING HOST GENES IN HIV INFECTION$0
P01 · FY2000 · DE
NATURAL HISTORY OF ANAL NEOPLASIA--ACTG 216$0
M01 · FY2000 · RR